Onset of effects of testosterone treatment and time span until maximum effects are achieved - PubMed (original) (raw)

Review

. 2011 Nov;165(5):675-85.

doi: 10.1530/EJE-11-0221. Epub 2011 Jul 13.

Affiliations

Review

Onset of effects of testosterone treatment and time span until maximum effects are achieved

Farid Saad et al. Eur J Endocrinol. 2011 Nov.

Abstract

Objective: Testosterone has a spectrum of effects on the male organism. This review attempts to determine, from published studies, the time-course of the effects induced by testosterone replacement therapy from their first manifestation until maximum effects are attained.

Design: Literature data on testosterone replacement.

Results: Effects on sexual interest appear after 3 weeks plateauing at 6 weeks, with no further increments expected beyond. Changes in erections/ejaculations may require up to 6 months. Effects on quality of life manifest within 3-4 weeks, but maximum benefits take longer. Effects on depressive mood become detectable after 3-6 weeks with a maximum after 18-30 weeks. Effects on erythropoiesis are evident at 3 months, peaking at 9-12 months. Prostate-specific antigen and volume rise, marginally, plateauing at 12 months; further increase should be related to aging rather than therapy. Effects on lipids appear after 4 weeks, maximal after 6-12 months. Insulin sensitivity may improve within few days, but effects on glycemic control become evident only after 3-12 months. Changes in fat mass, lean body mass, and muscle strength occur within 12-16 weeks, stabilize at 6-12 months, but can marginally continue over years. Effects on inflammation occur within 3-12 weeks. Effects on bone are detectable already after 6 months while continuing at least for 3 years.

Conclusion: The time-course of the spectrum of effects of testosterone shows considerable variation, probably related to pharmacodynamics of the testosterone preparation. Genomic and non-genomic effects, androgen receptor polymorphism and intracellular steroid metabolism further contribute to such diversity.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Time-course on body composition and strength.

Figure 2

Figure 2

Time-course on lipids.

Figure 3

Figure 3

Time-course on glucose and insulin.

Figure 4

Figure 4

Time-course on sexual parameters.

Figure 5

Figure 5

Time-course on hematocrit and prostate.

References

    1. Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clinical Endocrinology. 2006;65:275–281. doi: 10.1111/j.1365-2265.2006.02618.x. - DOI - PubMed
    1. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. Journal of Clinical Endocrinology and Metabolism. 2006;91:4335–4343. doi: 10.1210/jc.2006-0401. - DOI - PubMed
    1. Bancroft J. The endocrinology of sexual arousal. Journal of Endocrinology. 2005;186:411–427. doi: 10.1677/joe.1.06233. - DOI - PubMed
    1. Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clinical Endocrinology. 2003;58:632–638. doi: 10.1046/j.1365-2265.2003.01764.x. - DOI - PubMed
    1. Isidori AM, Greco EA, Aversa A. Androgen deficiency and hormone-replacement therapy. BJU International. 2005;96:212–216. doi: 10.1111/j.1464-410X.2005.05603.x. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources